Do you have a candidate therapeutic antibody that has suboptimal manufacturing characteristics such as low yield, high aggregation, or purification difficulties? Our dedicated team of antibody experts leverages 25 years of expertise our proprietary AI technology to transform your antibody into a successful therapeutic. Our antibody developability improvement service helps you make informed decisions, saving you time and resources in the drug development process. With 3 therapeutic antibodies on the market and 30+ antibodies in preclinical and clinical phases of development, you can trust us to deliver the insights you need to avoid antibody developability pitfalls and accelerate your clinical project.
Go/No Go Steps
Our process includes go/no-go steps, giving you control while we take on the risks.
You gain full ownership of the modified antibodies produced.
Proprietary AI Tool
Revolutionary antibody developability AI that takes the guesswork out of antibody optimization, providing unmatched precision and efficacy.
Decreased Time to Market
Accelerated commercialization through early identification of clinical shortcomings and streamlined antibody development.
Maximized Antibody Performance Insights
We perform a comprehensive biophysical analysis including antibody aggregation, antigen affinity, antibody interactions, and thermal stability.
Enhanced antibody developability results in greater success rates, improved efficiency, and accelerated time-to-market.
We keep you informed of every project milestone so that you can track our progress and ensure that we stay on target and within budget.
High Level of Customization
Our expert team can transform your monoclonal antibody into a potent therapy by customizing it into an ADC or bispecific antibody.
Step 1: Feasibility Study
Step 2: Developability via AI Tool
Step 3: Expression of Recombinant Variants
Recombinant variants are expressed in XtenCHO cells and the following are delivered:
Step 4: Test Variants for Increased Developability
Recombinant antibody production
Stable Cell Line Development
Therapeutic antibody production
At ProteoGenix, we are proud to offer our clients antibody developability improvement services that can transform your research into life-saving treatments.
Costly delays and clinical failures can be prevented by simply identifying the developability profile of an antibody during the early stages of the drug development process. You can take the risk to analyze and improve your antibody’s developability in-house or you can hire an expert team to do it for you.
At ProteoGenix, we have the tools and experience needed to rigorously evaluate your antibody’s developability profile to help you circumvent the pitfalls associated with antibody manufacturing, clinical development, and the evaluation of clinical efficacy. We do this by leveraging our team’s 25 years of average experience and artificial intelligence to take the guesswork out of antibody developability. By identifying potential issues early, we help our clients optimize their development pipeline, reduce costs, and bring effective treatments to patients faster.
Our antibody developability services involve evaluating and optimizing the physical and chemical properties of your antibody to increase the probability it becomes a licensed biologic.
This includes a range of services such as assessing the antibody’s stability, liabilities, solubility, aggregation propensity, immunogenicity, and affinity to its target antigen. Other services include evaluating the antibody’s manufacturability, such as assessing the yield and purity of the antibody during production or optimizing the antibody’s formulation to improve its shelf life and stability.
Here is what you can expect when using our antibody developability improvement service:
You have the option to proceed to the next stage and allow ProteoGenix to rigorously test the biophysical properties of your antibody variants (the last Go/No-Go decision point).
Our antibody developability improvement services identify and address potential issues early on in the drug development process, to fast-track your antibody’s progression from bench to bedside.
There are various antibody development assays that we can perform to assess and improve the developability of antibodies. Here are some examples:
Antibody Yield Assessment: Our antibody yield analysis measures the amount of antibody produced among different antibody variants during the manufacturing process to assess their manufacturing potential. This helps to ensure that the most potent clinical antibody variant is selected that also has the best manufacturing profile. This step ensures cost-effective and efficient production of therapeutic antibodies.
Modifying an antibody, such as creating a bispecific antibody or an antibody-drug conjugate (ADC), can change its developability profile. The process of modifying an antibody can introduce new structural features, such as additional domains or conjugated drug molecules, that can affect the antibody’s stability, solubility, and antigen-binding properties.
Therefore, it is important to evaluate the developability of modified antibodies early in the drug development process, to ensure that the modifications do not adversely affect the antibody’s therapeutic properties or its ability to be manufactured at scale. Additionally, modifying an antibody can require new analytical methods and manufacturing processes, which can also impact the developability of the final product.
The assessment of bispecific antibody developability can involve some additional considerations compared to a traditional monoclonal antibody. This is because the dual antigen-binding properties of bispecific antibodies can impact their developability.
Some of the specific considerations when assessing the developability of a bispecific antibody include:
The assessment of the developability of a bispecific antibody involves similar considerations to monoclonal antibodies but with some additional factors specific to the bispecific format. Therefore, it is important to tailor your antibody developability goals to the final modified antibody for the best results.
There are different ways to assess the developability of an antibody-drug conjugate (ADC) antibody compared to a traditional monoclonal antibody. ADCs are complex molecules that consist of an antibody linked to a cytotoxic drug, and this complexity can affect their developability.
Some of the key factors to consider when assessing the developability of an ADC antibody include:
To ensure the successful development of an antibody-drug conjugate (ADC) antibody, it is crucial to assess its developability using methods that are specifically tailored to its unique characteristics. This can be achieved by either conducting the developability assessment yourself or by working with antibody experts who have the knowledge, skills, and tools to improve your antibody’s developability.
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.